Press Releases

 

Ovation Study/Ovarian Cancer

  Date Title and Summary View
Nov 13, 2017
Expert Advisory Board Endorses Randomized Phase I/II Trial in Newly Diagnosed Stage III and IV Ovarian Cancer GEN-1 Immunotherapy to Enter Phase I/II Clinical Study in the First Half of 2018 Following a Phase IB Trial Demonstrating 100% Disease Control, 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated...
Nov 13, 2017
Expert Advisory Board Endorses Randomized Phase I/II Trial in Newly Diagnosed Stage III and IV Ovarian Cancer GEN-1 Immunotherapy to Enter Phase I/II Clinical Study in the First Half of 2018 Following a Phase IB Trial Demonstrating 100% Disease Control, 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated...
Oct 3, 2017
100% Disease Control; 86% Objective Response Rate and 86% R0 & R1 Surgical Resection Rate in All Patients Treated in Four Dose-Escalating Cohorts Clear Evidence of Biological Activity Including Dose Dependent Increases in Inflammatory Cytokines (IL-12 and IFN-g), Decreases in VEGF Levels and No Dose Limiting Toxicities Expert Advisory Board E...
Aug 24, 2017
LAWRENCEVILLE, N.J., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided an update on its OVATION Study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients wit...
Aug 2, 2017
LAWRENCEVILLE, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced findings from the translational research data from its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of newly-diagnosed...
Jul 5, 2017
86% Objective Response Rate (ORR) in Phase IB Dose Escalating Study 100% ORR and 100% R0 (Margin Negative) Surgical Resection Rate at Highest Dose Cohort Increased Ratio of CD8+ Cells to Immunosuppressive T-cells Observed in 75% of Patients Indicating a Shift to a Pro-Immune Stimulatory Environment LAWRENCEVILLE, N.J., July 05, 2017 (GLOBE...
Jun 5, 2017
100% disease control rate and 86% objective response rate reported All patients at the highest dose demonstrated an objective response rate - partial (80%) or complete (20%) response rate At the highest dose, 100% of patients achieved a R0, margin-negative, resection LAWRENCEVILLE, N.J., June 05, 2017 (GLOBE NEWSWIRE) -- Celsion Corporati...
Apr 20, 2017
LAWRENCEVILLE, N.J., April 20, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided an update on its OVATION Study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients wi...
Jan 17, 2017
Fourth Cohort of Patients Continues to Show Clinically Meaningful Responses in the Evaluation of GEN-1, A Novel IL-12 DNA-based Immunotherapy, in Combination with the Standard of Care LAWRENCEVILLE, N.J., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced data from the fourth cohort of patients in its Phase Ib ...
Dec 1, 2016
LAWRENCEVILLE, N.J., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that the independent Data Safety Monitoring Board (DSMB) has completed its safety review of data from the first four patient cohorts in the ongoing Phase 1b OVATION Study.  Based on the DSMB's recommendation, the study will continue as planned...
Page:
1
NextLast
= add release to Briefcase
Share This